Financial PerformanceShares are expected to largely retrace recent strength following a slower-than-expected finish to FY24, marked by further deal cycle elongation and FX headwinds.
Growth IndicatorsForward-looking indicators of growth disappointed with billings and cRPO growth of ~5% y/y, with consensus estimates closer to 11%.
GuidanceThe guidance for 2025 total revenue growth was below outlook, with lower visibility on sales improvements beyond FX.